UK-US Trade Deal Locks NHS into £44.7 Billion Medicines Spend by 2036, Forcing Service Cuts

The deal announced 1 December 2025 alters NICE thresholds from £20,000–£30,000 to £25,000–£35,000 per QALY and lowers the VPAG rebate from 23% to 14.5%, doubling new-medicines spending from 0.3% to 0.6% of GDP. BMJ modelling projects annual English NHS costs rising to £8.8 billion by 2036, displacing cardiovascular, cancer and respiratory care and producing 229,000 excess deaths, or 291,000 when adult social-care knock-ons are included.

These fiscal linkages expose how a tariff-free export concession for UK pharma exports directly reallocates routine NHS budgets. The unpublished Department of Health impact assessment leaves parliament without evidence on whether claimed innovation gains will offset measurable mortality rises. Parallel OBR GDP forecasts and NICE displacement studies indicate every £1 billion diverted adds £118 million to local-authority social-care costs.

Without ring-fenced funding, Integrated Care Boards will face immediate 2026–28 rationing decisions. The next required step is release of the full impact assessment and independent modelling of net population-health effects under alternative rebate and threshold scenarios.